Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals.

[1]  Eva Forssell-Aronsson,et al.  Dosimetric comparison of radionuclides for therapy of somatostatin receptor expressing tumours , 2000 .

[2]  H. Biersack,et al.  Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases , 2000, European Journal of Nuclear Medicine.

[3]  B. Hsieh,et al.  Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases. , 1999, Nuclear medicine and biology.

[4]  B. Hsieh,et al.  Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes. , 1999, Nuclear medicine and biology.

[5]  S. Mirzadeh,et al.  Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  S. Mirzadeh,et al.  Rhenium‐188 microspheres: A new radiation synovectomy agent , 1998, Nuclear medicine communications.

[7]  H. Maxon,et al.  Rhenium-188(Sn)HEDP for treatment of osseous metastases. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  T. Waldmann,et al.  Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  R. Wilkinson.  Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  B. Hsieh,et al.  Radiolabelling of Lipiodol with generator-produced 188Re for hepatic tumor therapy. , 1996, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[11]  S. Mirzadeh,et al.  Processing of reactor-produced 188W for fabrication of clinical scale alumina-based 188W/188Re generators , 1994 .

[12]  J. Nesland,et al.  Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model. , 1992, Gynecologic oncology.

[13]  R. Buckman,et al.  Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3 , 1992, Gynecologic oncology.

[14]  A. D. Van den Abbeele,et al.  5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. , 1991, International journal of radiation oncology, biology, physics.

[15]  D. Snook,et al.  Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Coleman,et al.  Alpha particle radio-immunotherapy: animal models and clinical prospects. , 1989, International journal of radiation oncology, biology, physics.

[17]  A. Herbst,et al.  The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma. , 1989, American journal of obstetrics and gynecology.

[18]  B. Hsieh,et al.  Ascorbic acid/saline eluant increases 188Re yields after “wet” storage of 188W/188Re generators , 1996 .

[19]  R. Pattillo,et al.  Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  V. Spitzer,et al.  Normal appearance and reproducibility of liver-spleen studies with Tc-99m sulfur colloid and Tc-99m microalbumin colloid. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.